An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

It is a hallucinogenic drug, and is a controlled substance designed for use as an aesthetics. It also has now been touted for ...